Anlotinib Recruiting Phase 2 Trials for Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04004572Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
NCT03618238Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma